Nicotinic acetylcholine receptors (nAChRs) in the ventral tegmental area (VTA) and their effects on signaling in the nucleus accumbens (NAc) are important for the behavioral actions of nicotine related to addiction. Our hypothesis is that there is a dissociation between nicotine reward and locomotor activation. We hypothesize that nicotine reward necessitates activation of D1 receptors and increased CREB activity in the NAc shell, whereas DA receptor activation in the NAc core is sufficient for locomotor activation, and CREB activity is not necessary. We have used transgenic mice with expression of the beta2-subunit of the nAChR on VTA neurons that project to the NAc core to test the idea that these receptors are sufficient for nicotine-dependent locomotor activation. Preliminary studies show that these mice show relatively normal nicotine-dependent locomotor activation but do not show a place preference for nicotine or activation of CREB in the NAc core.
Aim 1 of this project will be to determine whether CREB activity in the NAc shell, but not core, is critical for nicotine reward using viral-mediated gene transfer and complementary pharmacological approaches. In addition we will determine whether the balance between D1 vs. D2 signaling is important for CREB activity in the NAc shell or core, and nicotine reward.
Aim 2 will determine whether DA release in the NAc core and not the shell is sufficient for nicotine-mediated locomotor activation, and determine the subsequent effects on CREB activation in the NAc. These experiments are significant because they could explain the very sharp dose-response function for nicotine reward and may provide new points of intervention to support smoking cessation. They will help identify the molecular mechanisms and signaling pathways involved in nicotine locomotion and reward, and determine the role of D1 and D2 receptor activation in these behaviors. These studies will test the hypothesis that CREB activity in the NAc shell integrates D1 and D2 signaling and is a critical output underlying nicotine reward.

Public Health Relevance

We know that nicotine is the primary agent in tobacco that leads to addiction. Nicotine changes the strength of communication between nerve cells and this is thought to be responsible for the long-term changes in behavior that results from smoking, including long-lasting increases in cigarette craving and the likelihood to relapse. We have shown that activity of CREB, a molecule that is known to be important for changing the connections between nerve cells, is necessary for nicotine to be rewarding in mice. We have also shown using genetically-manipulated mice that nicotine receptors on a group of nerve cells in the brain's reward center that communicate with what is called the core of the nucleus accumbens are sufficient for the ability of nicotine to act as a stimulant, but not nicotine reward. We believe that nicotine receptors on nerve cells that communicate with the nucleus accumbens shell are important for nicotine reward, whereas nicotine receptors on nerve cells that communicate with the nucleus accumbens core are important for nicotine's stimulant properties. These two pathways can be distinguished genetically, but may also be sensitive to different drugs. We propose that targeting the molecules that lead to long- lasting changes in the communication between nerve cells in the nucleus accumbens shell could lead to new therapies for smoking cessation.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
Neurobiology of Motivated Behavior Study Section (NMB)
Program Officer
Pollock, Jonathan D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Schools of Medicine
New Haven
United States
Zip Code
Mineur, Yann S; Einstein, Emily B; Bentham, Matthew P et al. (2015) Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine. Neuropsychopharmacology 40:938-46
McClure-Begley, T D; Papke, R L; Stone, K L et al. (2014) Rare human nicotinic acetylcholine receptor ?4 subunit (CHRNA4) variants affect expression and function of high-affinity nicotinic acetylcholine receptors. J Pharmacol Exp Ther 348:410-20
Mazei-Robison, Michelle S; Appasani, Raghu; Edwards, Scott et al. (2014) Self-administration of ethanol, cocaine, or nicotine does not decrease the soma size of ventral tegmental area dopamine neurons. PLoS One 9:e95962
Higley, Michael J; Picciotto, Marina R (2014) Neuromodulation by acetylcholine: examples from schizophrenia and depression. Curr Opin Neurobiol 29:88-95
Mineur, Yann S; Taylor, Seth R; Picciotto, Marina R (2014) Calcineurin downregulation in the amygdala is sufficient to induce anxiety-like and depression-like behaviors in C57BL/6J male mice. Biol Psychiatry 75:991-8
Taylor, Seth R; Badurek, Sylvia; Dileone, Ralph J et al. (2014) GABAergic and glutamatergic efferents of the mouse ventral tegmental area. J Comp Neurol 522:3308-34
Picciotto, Marina R; Mineur, Yann S (2014) Molecules and circuits involved in nicotine addiction: The many faces of smoking. Neuropharmacology 76 Pt B:545-53
Jung, Yonwoo; Mulholland, Patrick J; Wiseman, Shari L et al. (2013) Constitutive knockout of the membrane cytoskeleton protein beta adducin decreases mushroom spine density in the nucleus accumbens but does not prevent spine remodeling in response to cocaine. Eur J Neurosci 37:1-9
Yang, Yang; Paspalas, Constantinos D; Jin, Lu E et al. (2013) Nicotinic *7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc Natl Acad Sci U S A 110:12078-83
Neugebauer, Nichole M; Einstein, Emily B; Lopez, Maria B et al. (2013) Morphine dependence and withdrawal induced changes in cholinergic signaling. Pharmacol Biochem Behav 109:77-83

Showing the most recent 10 out of 54 publications